Skip to main content
Equibles
FLNA logo

FLNA · Filana Therapeutics, Inc.

Track FLNA — free

Use FLNA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research FLNA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.69 +0.01 (+0.95%) At close · Oct 20
Rebalance outlook locked
Market Cap
$33.26M
Shares
48.31M
Volume · Oct 20 198.36K Avg daily vol (3M) 2M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.69 Open$0.67 Day$0.67–0.70 52W close$0.68–4.41 Avg vol 30d4.0M Short int5.9M · 12.2% float · 1.0d Short vol64% Last earningsMay 7, 2026 DataJan 2020–Oct 2026 Filing10-Q · Jul 29

Up next

Next earnings call
Nov 4, 2027 Est · unconfirmed · in 54 wks
Latest filing: 10-Q
filed Jul 29, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$41.12M
Trailing 12 months
Net income (TTM)
−$42.28M
Trailing 12 months
Revenue growth YoY
+1,328.0%
Year over year
Operating margin
76.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$82.68M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.7%
Year over year · more shares
Price change (1Y)
-84.1%
Trailing year
Short interest
12.2%
Latest settlement · 1.0 days to cover
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 17.3 · elevated Equity put/call 0.56
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −51%
below
Price vs 50-day avg −18%
below
RSI (14) 39
neutral
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −33%
trailing
6-month return −52%
trailing
YTD return −65%
this year
Relative strength −60%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
6 of 87 funds reported for Sep 30 · net -275 sh shares
Insider flow Accumulating
Net +$356.3K over 90 days · 0% sells
Short interest Falling
12.18% of float · ▼ -5.3% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
87 holders — near 3-yr low, contrarian setup
Squeeze score 55
elevated · 0–100
Fundamentals
Weak
Revenue growth +278%
Y/Y
EPS growth −29%
Y/Y
Free cash flow $-32.8M
Quant / Vol
risk profile
Very High
Volatility 86%
annualized · 1-yr
Max drawdown −85%
past year
ATR 10.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Jul 29, 2026
second-half 2026
Net cash used in operations for second-half 2026 Initiated $11M – $15M
year-end 2026
Unrestricted cash at year-end 2026 $36M – $40M
Prior guidance period ended · from the 8-K filed Nov 12, 2025
Cash and cash equivalents · year-end 2025 $92M – $96M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−51% Bearish
Price vs 50-day avg
−18% Bearish
RSI (14)
39 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
6 of 87 funds reported for Sep 30 · net -275 sh shares
Insider flow Accumulating
Net +$356.3K over 90 days · 0% sells
Short interest Falling
12.18% of float · ▼ -5.3% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
87 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $1 Now $1 · 0% Range high $4
vs 200-day avg -51% vs 50-day avg -18%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
FLNA
Filana Therapeutics, Inc.
this stock
$33.26M -65.2% +277.6% — 12.2%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.07B +13.5% +46.2% 29.9 1.8%
MRNA
Moderna, Inc.
 $90.58B +720.9% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.51B +4.6% +20.8% 19.4 2.1%
CSLLY
Csl Ltd
 $66.34B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
86
% held
27.5%
Reported
6 of 87
Top holder
VANGUARD CAPITAL MANAGEME…
Held Float
View
Held by Funds
Fund positions
27
View
Short & Settlement
Short Interest Falling
Shares short
5.9M
Days to cover
1.0d
Change
-332.6K sh
View
Short Volume
Short vol %
64%
As of
Oct 20, 2026
Short Total
View
Fails to Deliver
FTD shares
25.7K
Value
$26.5K
As of
Sep 23, 2026
View
Off-Exchange
Off-exchange %
59.2%
Week of
Sep 14, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$356.3K
Buyers / Sellers
1 / 0
Buyers Sellers
View
Congressional Trades Buy
Member
Christopher L. Jacobs
Amount
$1.0K–$15.0K
Traded
Dec 12, 2022
View
Financials
Financials
Net income (FY)
$-91.0M
EPS diluted
$-1.88
View
Filings
SEC Filings
Latest
8-K
Filed
Oct 20, 2026
This year
15

On October 16, 2026, the Fifth Circuit vacated the Texas District Court’s class certification order in Filana Therapeutics, Inc.’s securities class action, finding the court misapplied the legal standard; further class-certification proceedings will proceed on remand.

View
Proposed Sales
Value
$7.6K
Shares
2.0K
Filed
Dec 2, 2024
View
Earnings & Events
Webcasts
Last webcast
May 7, 2026
View
Investor Relations
Latest news
Filana Therapeutics to Participat…
Published
Oct 9, 2026
View

Performance

5D 20D 120D MTD YTD
FLNA -7.4% -33.2% -52.2% -22.3% -65.2%
SPY -1.2% -0.6% +8.1% +0.8% +12.8%
vs SPY -6.2% -32.6% -60.3% -23.1% -78.0%
Key facts CIK 1069530 CUSIP 14817C107 13F (30d) 7 filings 7 filers Visit website Investor relations